|
|
Effect of homoharringtonine on lapoptosis and proliferation of leukemia cells and its inhibitory effect on Ras/Raf/MEK pathway |
QI Haiyan LAN Jianping SONG Xiaolu WANG Xiaogang WANG Wensong |
Department of Hematology, Affiliated People’s Hospital of Hangzhou Medical College Zhejiang Provincial People’s Hospital, Zhejiang Province, Hangzhou 310014, China
|
|
|
Abstract Objective To investigate the effect of homoharringtonine (HHT) on apoptosis and proliferation of leukemia cells and its inhibitory effect on Ras/Raf/MEK pathway. Methods The logarithmic growth phase K562 and Kasum-1 cells were taken for study and treated with HHT of 0, 10, 20 , and 50 ng/ml, respectively. MTT was used to detect relative cell viability, clone formation assay was used to detect the number of cell clones, cell IC50 was calculated at 24, 48, and 72 hours, flow cytometry was used to detect the level of apoptosis, and Western blot was used to detect the relative levels of Ras/Raf/MEK pathway proteins and apoptosis-related proteins. Results At 24, 48, and 72 hours, the IC50 of HHT on K562 cells was 80.69, 65.28, and 50.76 ng/ml, respectively. The IC50 of HHT on Kasum-1 cells was 85.16, 70.11, and 51.14 ng/ml, respectively. When cultured for 24, 48, and 72 h, the survival rate of 10, 20 and 50 ng/ml HHT cells was lower than 0 ng/ml, and the survival rate of 20 and 50 ng/ml HHT cells was lower than 10 ng/ml. The survival rate of 50 ng/ml HHT cells was lower than that of 20 ng/ml HHT cells, and the differences were statistically significant (P<0.05). The clones of 10, 20 and 50 ng/ml HHT cells were all lower than 0 ng/ml; the clones of 20 and 50 ng/ml HHT cells were all lower than 10 ng/ml HHT cells; the clones of 50 ng/ml HHT cells were all lower than 20 ng/ml HHT cells, and the differences were statistically significant (P<0.05). The apoptosis rate of 10, 20, and 50 ng/ml HHT cells was higher than that of 0 ng/ml HHT cells, the apoptosis rate of 20 and 50 ng/ml HHT cells was higher than that of 10 ng/ml HHT cells, and the apoptosis rate of 50 ng/ml HHT cells was higher than that of 20 ng/ml HHT cells, and the differences were statistically significant (P<0.05). The expression levels of RAS, p-cRAF, and p-MEK protein at 10, 20, and 50 ng/ml HHT were all lower than 0 ng/ml HHT, and the expression levels of RAS, p-cRAF, and p-MEK protein at 20 and 50 ng/ml HHT were all lower than 10 ng/ml HHT. The expression levels of RAS, p-cRAF, and P-MEK at 50 ng/ml HHT were lower than those of 20 ng/ml HHT, and the differences were statistically significant (P<0.05). Survivan expression levels at 10, 20, and 50 ng/ml HHT were lower than 0 ng/ml HHT, Cleaved caspase-3 and Cleaved PARP were higher than 0 ng/ml HHT. Survivan expression at 20 and 50 ng/ml HHT was lower than that at 10 ng/ml HHT. Survivan expression levels were lower than 10, and 50 ng/ml HHT, respectively, Cleaved caspase-3 and Cleaved PARP expression levels were higher than 20 ng/ml HHT. The protein expression levels of Cleaved caspase-3 and Cleaved PARP were higher than 20 ng/ml HHT, and the differences were statistically significant (P<0.05). Conclusion HHT can inhibit the activity of Ras/Raf/MEK pathway, inhibit the proliferation of leukemia cells, and promote apoptosis of leukemia cells.
|
|
|
|
|
[1] Rocca A,Braga L,Volpe MC,et al. The Predictive and Prognostic Role of RAS-RAF-MEK-ERK Pathway Alterations in Breast Cancer:Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets [J]. Cancers (Basel),2022,14(21):5306.
[2] Jin H,Zhang Y,Yu S,et al. Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter,Phase 2 Trial [J]. J Hematol Oncol,2023,16(1):42.
[3] Li J,Huang Y,Hou Y,et al. High efficacy of azacitidine combined with homoharringtonine,idarubicin,and cytarabine in newly diagnosed patients with AML:A single arm,phase 2 trial [J]. Front Oncol,2022,12:1069246.
[4] Plett R,Mellor P,Kendall S,et al. Homoharringtonine demonstrates a cytotoxic effect against triple-negative breast cancer cell lines and acts synergistically with paclitaxel [J]. Sci Rep,2022,12(1):15663.
[5] PorcùE,Maule F,Manfreda L,et al. Identification of Homoharringtonine as a potent inhibitor of glioblastoma cell proliferation and migration [J]. Transl Res,2023,251:41-53.
[6] Zhang G,Song Y,Wan L,et al. Treatment of STAT5b-RARA positive acute promyelocytic leukemia by Venetoclax combining with homoharringtonine,cytarabine:A case report and literature review [J]. Blood Sci,2022,4(2):93-96.
[7] Watari A,Fujiwara K,Yagi K,et al. Homoharringtonine is a transdermal granular permeation enhancer [J]. Biochem Biophys Res Commun,2022,616:140-144.
[8] 李芬芬,季斌.吉西他滨联合放射对人胰腺癌CFPAC-1细胞株裸鼠移植瘤EphB4、Caspase3表达的影响[J].实用癌症杂志,2022,37(10):1570-1574,1595.
[9] Choi EY,Jung GH,Woo JS,et al. Dendropanax morbiferus H. Lus Leaf Extract Inhibits the Proliferation of MDA-MB-231 Breast Cancer Cells and Induces Apoptosis via the MAPK Pathway In Vitro and In Vivo [J]. Anticancer Res,2023,43(7):3047-3056.
[10] Kim T,Kang JK,Hyun CG. 6-Methylcoumarin Promotes Me- lanogenesis through the PKA/CREB,MAPK,AKT/PI3K,and GSK3 6-Methylcoumarin Promotes Mel [J]. Molecules,2023,28(11):4551.
[11] Wan W,Xiao W,Pan W,et al. Isoprenylcysteine carboxyl methyltransferase is critical for glioblastoma growth and survival by activating Ras/Raf/Mek/Erk [J]. Cancer Chemother Pharmacol,2022,89(3):401-411.
[12] Yang X,Shang P,Yu B,et al. Combination therapy with miR34a and doxorubicin synergistically inhibits Dox-resistant breast cancer progression via down-regulation of Snail through suppressing Notch/NF-κB and RAS/RAF/MEK/ ERK signaling pathway [J]. Acta Pharm Sin B,2021,11(9):2819-2834.
[13] Cortes J,Lipton JH,Rea D,et al. Phase 2 Study of Subcutaneous Omacetaxine Mepesuccinate After Tki Failure in Patients With Chronic-Phase Cml With T315i Mutation [J]. Blood,2012,120(13):2573-2580.
[14] Jin J,Wang JX,Chen FF,et al. Homoharringtonine-Based Induction Regimens for Patients With De-Novo Acute Mye- loid Leukaemia:A Multicentre,Open-Label,Randomised,Controlled Phase 3 Trial [J]. Lancet Oncol,2013,14(7):599-608.
[15] Karmokar PF,Moniri NH. Free-fatty acid receptor-1 (FFA1/ GPR40) promotes papillary RCC proliferation and tumor growth via Src/PI3K/AKT/NF-κB but suppresses migration by inhibition of EGFR,ERK1/2,STAT3 and EMT [J]. Cancer Cell Int,2023,23(1):126.
[16] Mehdiüremi?鬤 M,üremi?鬤 N,Türk?觟zy Cucurbitacin E shows synergistic effect with sorafenib by inducing apoptosis in hepatocellular carcinoma cells and regulates Jak/ Stat3,ERK/MAPK,PI3K/Akt/mTOR signaling pathways [J]. Ster- oids,2023,22:109261.
[17] Ware KE,Thomas BC,Olawuni PD,et al. A synthetic lethal screen for Snail-induced enzalutamide resistance identifies JAK/STAT signaling as a therapeutic vulnerability in pros- tate cancer [J]. Front Mol Biosci,2023,10:1104505.
[18] Wang L,You LS,Ni WM,et al. Beta-Catenin and Akt Are Promising Targets for Combination Therapy in Acute Myeloid Leukemia [J]. Leuk Res,2013,37(10):1329-1340.
[19] Zhang W,Lu Y,Zhen T,et al. Homoharringtonine Synergy With Oridonin in Treatment of T (8,21) Acute Myeloid Leu- kemia [J]. Front Med,2019,13(3):38897.
[20] Shi X,Zhu M,Gong Z,et al. Homoharringtonine suppresses LoVo cell growth by inhibiting EphB4 and the PI3K/AKT and MAPK/EKR1/2 signaling pathways [J]. Food Chem Toxicol,2020,136:110960.
[21] Liu HY,Dong TX,Li ZZ,et al. Homoharringtonine inhibits the progression of hepatocellular carcinoma by suppressing the PI3K/AKT/GSK3β/Slug signaling pathway [J]. Neoplasma,2021,68(5):924-937.
[22] Sun Y,Dai J,Jiao R,et al. Homoharringtonine inhibits fibroblasts proliferation,extracellular matrix production and reduces surgery-induced knee arthrofibrosis via PI3K/AKT/ mTOR pathway-mediated apoptosis [J]. J Orthop Surg Res,2021,16(1):9.
[23] 高小凤,张坤,张丽君,等.高三尖杉酯碱联合用药对急性髓系白血病细胞的增殖抑制[J].华西药学杂志,2021, 36(1):35-38.
[24] 丁亦含,吴晶晶,王倩,等.高三尖杉酯碱通过mTOR通路诱导慢性髓系白血病K562细胞凋亡[J].中国实验血液学杂志,2018,26(1):105-109.
[25] Guo L,Bai Y,Ji S,et al. MicroRNA-98 suppresses cell growth and invasion of retinoblastoma via targeting the IGF1R/ k-Ras/Raf/MEK/ERK signaling pathway[J]. Int J Oncol,2019,54(3):807-820.
[26] Sakai H,Shiina I,Shinomiya T,et al. BRAP2 inhibits the Ras/Raf/MEK and PI3K/Akt pathways in leukemia cells,thereby inducing apoptosis and inhibiting cell growth [J]. Exp Ther Med,2021,21(5):463. |
|
|
|